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Abstract
Background: The lipodystrophic syndrome (LD) is a disorder resulting from selective damage of
adipose tissue by antiretroviral drugs included in therapy controlling human-immunodeficiency-
virus-1. In the therapy cocktail the nucleoside reverse transcriptase inhibitors (NRTI) contribute
to the development of this syndrome. Cellular target of NRTI was identified as the mitochondrial
polymerase-gamma and their toxicity described as a mitochondrial DNA (mtDNA) depletion
resulting in a mitochondrial cytopathy and involved in fat redistribution. No mechanisms offer
explanation whatsoever for the lipo-atrophic and lipo-hypertrophic phenotype of LD. To
understand the occurrence we proposed that the pO2 (oxygen partial pressure) could be a key
factor in the development of the LD. For the first time, we report here differential effects of NRTIs
on human adipose cells depending on pO2 conditions.
Results and discussion: We showed that the hypoxia conditions could alter adipogenesis
process by modifying expression of adipocyte makers as leptin and the peroxisome proliferator-
activated receptor PPARgamma and inhibiting triglyceride (TG) accumulation in adipocytes.
Toxicity of NRTI followed on adipose cells in culture under normoxia versus hypoxia conditions
showed, differential effects of drugs on mtDNA of these cells depending on pO2 conditions.
Moreover, NRTI-treated adipocytes were refractory to the inhibition of adipogenesis under
hypoxia. Finally, our hypothesis that variations of pO2 could exist between adipose tissue from
anatomical origins was supported by staining of the hypoxic-induced angiopoietin ANGPTL4
depended on the location of fat.
Conclusion:  Toxicity of NRTIs have been shown to be opposite on human adipose cells
depending on the oxygen availability. These data suggest that the LD phenotype may be a
differential consequence of NRTI effects, depending on the metabolic status of the targeted adipose
tissues and provide new insights into the opposite effects of antiretroviral treatment, as observed
for the lipo-atrophic and lipo-hypertrophic phenotype characteristic of LD.
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Background
Lipodystrophic syndrome (LD) is a disorder resulting
from selective damage to adipose tissue by antiretroviral
drugs used to control HIV infection. LD first emerged at
about the same time as viral protease inhibitors (PIs) were
first introduced but it is currently thought that both PIs
and a second class of anti-viral drugs – nucleoside reverse
transcriptase inhibitors (NRTI) – contribute to the devel-
opment of this syndrome [1]. Studies in vitro have shown
that PIs affect fat-cell differentiation and the expression of
adipose markers in the subcutaneous fat tissue of patients
with LD [2]. The cellular target of NRTI was identified as
the mitochondrial polymerase-γ involved in the mito-
chondrial DNA (mtDNA) repair and replication. NRTI
toxicity seems to involve mostly massive mtDNA deple-
tion, resulting in a mitochondrial cytopathy; it has also
recently been implicated in fat redistribution syndrome
(see for review [3-5]). In human primary preadipocytes,
NRTIs have been described to induce a strong mtDNA and
to affect the function of mitochondrial respiratory chain
[6]. Recent studies on 3T3-F442A preadipocytes exposed
to stavudine (d4T), zidovudine (AZT), ddC or didanosine
(ddl) showed that d4T, ZDV and ddC decreased adipocyte
mtDNA while ddl had no effects [7]. Furthermore, in vivo
mtDNA depletion in adipose cells has been shown to be
associated with a dysfunction of the mitochondrial oxida-
tive phosphorylation chain [8]. However, NRTIs were also
described to decrease transcription of mtRNA in absence
of depletion of mtDNA [9]. Moreover, they were shown to
alter expression of both mitochondrial and lipid metabo-
lism genes. These data suggest that NRTIs may also cause
mitochondrial dysfunction by other means than through
inhibition of DNA polymerase gamma and in this con-
text, disruption of expression of lipid metabolism genes
offers an explanation for NRTI-induced lipoatrophy [9].
Adipose tissue, which was once thought to function pri-
marily as a passive depot for the storage of excess lipid, is
now understood to play a much more active role in meta-
bolic regulation, secreting numerous proteins, including
leptin, resistin, adiponectin, acylation-stimulating pro-
tein, tumor necrosis factor-alpha and interleukin-6 (IL-6),
in response to various stimuli. These secreted proteins
have pleiotropic effects; their involvement in glucose and
fat metabolism may affect insulin resistance. Based on
their anatomical location, subcutaneous and visceral adi-
pose tissues may be involved in controlling the efficiency
of lipolysis or the metabolic disturbances associated with
visceral obesity, including glucose intolerance, hyperin-
sulinemia, insulin resistance, hypertension and dyslipo-
proteinemia (see for review[10]). Furthermore, levels of
adipokines and of vascular endothelial growth factor
(VEGF), IL-6 and the plasminogen-activator inhibitor-1
(PAI-1) released have been shown to be higher in visceral
than in abdominal subcutaneous tissue [11]. All of these
are hypoxia target genes and further suggesting that
hypoxia might regulate adipogenesis. Adipocyte differen-
tiation in vitro is inhibited under hypoxic conditions, indi-
cating that oxygen is an important physiological regulator
of adipogenesis [12]. Moreover, angiopoietin-like 4 pro-
tein (ANGPTL4), also known as PPARγ angiopoietin-
related (PGAR) or fasting-induced adipose factor (FIAF),
is a protein that has been reported to be expressed in adi-
pose tissue and placenta and associated with adipose dif-
ferentiation [13]. The angptl4  gene was recently
demonstrated to display hypoxia-induced expression in
various cell types and to modulate angiogenesis in tumor
and ischemic tissues, suggesting that this protein could
provide a link between metabolic disorders and the regu-
lation of angiogenesis by hypoxia [14,15].
Adipose tissue has been shown to have unique properties
in plasticity, a capacity for vascular remodeling, and sus-
ceptibility to angiogenesis inhibitors. These characteristics
result from the maintenance of immature adipose vessels,
which facilitates vascular/tissue remodeling [16]. In an
obese mouse model, angiogenesis inhibitors designed to
inhibit tumor growth were shown to reduce adipose tissue
mass by cutting off the blood supply [17]. The reciprocal
regulation of adipogenesis and angiogenesis was sug-
gested by blocking VEGF signaling, which inhibited adi-
pose tissue formation in vivo [18].
The redistribution of body fat in patients with LD entails
the visceral accumulation of white adipose tissue and sub-
cutaneous fat wasting. It remains unclear why adipose tis-
sue is affected differently in different regions of the body,
as in the lipo-atrophic and lipo-hypertrophic phenotype
characteristic of LD. Various hypothesis were proposed to
explain abnormal body-fat distribution in HIV-1-associ-
ated adipose redistribution syndrome. The neurological
hypothesis was bases on neuroanatomical studies show-
ing autonomic control of white adipose tissue by both the
sympathetic and parasympathetic branch, with separate
sets of autonomic neurons innervating either the subcuta-
neous or the visceral fat compartment. Fliers et al pro-
posed that adipose redistribution syndrome is mediated
by effects of antiretroviral treatment on the central nerv-
ous system and could indicate a change in autonomic bal-
ance resulting in redistribution of adipose tissue [19]. An
immunological hypothesis was also brought by the data
reporting that fat accumulation in the breast in women on
antiretroviral treatment was associated to a particular
immunologic profile characterized by good T-helper
activity and normalization of macrophage-derived
cytokines (IL-12, TNF-(alpha)) [20].
In order to investigate whatsoever O2 might have a role in
the LD phenotype, the effects of hypoxia on adipogenesis
were investigated. We demonstrated that hypoxia modi-Lipids in Health and Disease 2006, 5:27 http://www.lipidworld.com/content/5/1/27
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fied the pattern of production of crucial adipocyte factors,
including PPARγ, leptin, the angiogenic factors VEGF and
ANGPTL4. In addition, levels of the transcription factor
HIF-1α were stable in hypoxic preadipocyte nuclei. More-
over, triglyceride (TG) accumulation in adipocytes was
strongly inhibited during adipogenesis following
hypoxia. These data are consistent with pO2 (oxygen par-
tial pressure) variations having an effect on the molecular
and metabolic status of adipocytes. We then investigated
the toxicity of NRTI in adipose cells under normoxia and
hypoxia. We provide here the first demonstration that the
effects of NRTI treatment on adipose cells depend on pO2
in culture conditions. Finally, we tested the hypothesis
that pO2-adipogenesis-angiogenesis state differs in adi-
pose tissues from different anatomical origins, by studies
of hypoxia-induced angiopoietin ANGPTL4 expression in
sections of adipose tissue. Staining depended on the loca-
tion of fat deposits and the results obtained suggested that
staining was associated with hypoxic microenvironments,
which may be in a different metabolic state, thereby partly
accounting for differences in the response to NRTI treat-
ment.
These results provide new insights into the effects of
antiretroviral treatment, differently affecting different
regions of the body, as observed for the lipo-atrophic and
lipo-hypertrophic phenotype characteristic of LD.
Results
Effects of hypoxia on adipogenesis
We investigated whether low pO2 affected adipogenesis by
allowing human primary preadipocyte to differentiate in
the presence of the standard cocktail of adipogenic hor-
mones (+ MIX) under gaseous hypoxia (1% O2) or chem-
ical hypoxia (DFO). We then compared TG accumulation
with that in normoxia (20% O2) (Fig. 1A). Under nor-
moxia, 80 to 90% of preadipocytes differentiated into
mature adipocytes loaded with TG droplets, as demon-
strated by colorimetric quantification of Red-Oil staining.
However, adipocyte differentiation was inhibited when
adipogenesis was induced under hypoxia (DFO or 1%
O2), consistent with previous results for the preadipocyte-
like L1 cell line [12].
We investigated the effect of hypoxia on the production of
adipocyte factors, mRNA synthesis for the transcription
factor PPARγ, and the adipokine leptin in confluent
preadipocytes cultured under DFO treatment. We also
assessed expression of the pro-angiogenic vascular
endothelial growth factor VEGF, which has been reported
to be a hypoxia response factor upregulated in rodent adi-
pocyte cell lines treated with drugs mimicking hypoxia
[21]. PPARγ cDNA levels decreased (Fig. 1B), despite
increases in leptin and VEGF levels, showing that hypoxia
can modulate key markers of adipogenesis and angiogen-
esis in human preadipocytes.
The cellular response to hypoxia is strongly linked to the
stabilization of HIF-1α, which regulates hypoxia-respon-
sive genes. We investigated HIF-1α stabilization and lep-
tin protein production in preadipocytes cultured under
hypoxia (Fig. 1C). Following the exposure of cells to
hypoxia (+DFO), immunofluorescence staining showed,
as expected, accumulation of the transcription factor HIF-
1α in the nucleus (a) and of leptin protein in cytoplasmic
vesicles (b). Double-staining experiments indicated that
leptin was produced mostly in preadipocytes expressing
the hypoxic marker HIF-1α (c). These data strongly sug-
gest that pO2 variations may affect the molecular and met-
abolic status of adipose cells.
Differential effects of NRTI treatment on human adipose 
cells cultured under different pO2
The cellular target of NRTI has been identified as the mito-
chondrial polymerase γ, and mtDNA depletion has been
observed in treated cells. We investigated the dual toxicity
of NRTI in fat deposits, taking into account the possible
effects of variations of pO2 on adipogenesis, by assessing
the toxicity of NRTI in adipose cells under normoxia and
hypoxia (Fig. 2). Quantification of mtDNA (Fig. 2A)
revealed that NRTI treatment induced severe mtDNA
depletion in preadipocytes maintained in normoxia (20%
O2). However, no NRTI-induced depletion was observed
in preadipocytes cultured in hypoxia (DFO), despite weak
decreases in mtDNA content the low pO2. We investigated
the effect of NRTI on metabolically active adipose cells by
quantifying mtDNA levels in mature adipocytes treated
with NRTI during differentiation (Fig. 2A). Adipocytes
gave similar results to preadipocytes: mtDNA depletion in
NRTI-treated cells under normoxia and no significant
depletion under hypoxia.
We assessed TG accumulation in mature adipocytes
treated with NRTI during differentiation (Fig. 2B). No TG
accumulation was detected in preadipocytes, with or with-
out NRTI. Lipid accumulation levels were similar in adi-
pocytes differentiated in normoxia and treated with NRTI
and in untreated cells. Differentiation was strongly inhib-
ited under hypoxia (Fig 1A and Fig 2B). Paradoxically,
NRTI-treated adipocytes were refractory to the inhibition
of adipogenesis under hypoxia, as cells accumulated TG to
levels similarly to cells under normoxia. In order to deter-
mine whether, in this condition, hypoxia can induce lipid
accumulation independently of adipocyte differentiation,
expression of the two adipocyte markers, PPARγ and lep-
tin, was evaluated (Fig 2C). Quantitative RT-PCR results
showed that NRTIs treatment (black bars) did not modify
PPARγ nor leptin gene expression in normoxia compared
to control cells (hatched bars). These data also showedLipids in Health and Disease 2006, 5:27 http://www.lipidworld.com/content/5/1/27
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that, as described in figure 1B, PPARγ gene expression was
Effects of hypoxia on adipogenesis Figure 1
Effects of hypoxia on adipogenesis. (A) Hypoxia inhibits TG accumulation. Cells were allowed to differentiate for 15 days 
with differentiation mix (black bars) under normoxia (20%), gaseous hypoxia (1%) or chemical hypoxia (100 μM DFO). TG 
accumulation was quantified by colorimetric determination of Red-Oil staining. Data are presented as optical density at 495 nm 
(OD495 nm). n = 4, ** p < 0.001. (B) Hypoxia modulated adipocyte gene expression. Confluent cells were treated for 24 hours with 
100 μM DFO (+) grey bars or were not treated (-) white bars. RNA was extracted and expression of the PPARγ, leptin and 
VEGF genes was followed by quantitative PCR. n = 2, ** p < 0.01. (C) Localization of HIF-1α and leptin protein in hypoxia-stimulated 
cells. Cells were treated for 24 hours with 100 μM DFO (+DFO) or were not treated (-DFO). Proteins were detected with 
mAB against HIF1-α tagged with a goat anti-mouse IgG coupled to FITC (a) or with mAB against leptin tagged with a goat anti-
rabbit IgG coupled to cy3 (b), or a co-staining (c).
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down regulated and leptin gene expression was up-regu-
lated in preadipocytes (P) treated by DFO compared with
normoxia (20%). However, in the treated adipocytes
(DFO, A, NRTI) where hypoxia did not inhibit differenti-
ation since the amount of lipids was maintained (Fig 2B),
expression of PPARγ was down regulated and the leptin
was up-regulated. These data suggest that, in this condi-
tion, hypoxia can induce lipid accumulation independ-
ently of adipocyte differentiation marker PPARγ, as
previously described by Fink et al [22].
Thus, the effect of NRTI depends on pO2 conditions.
Indeed, mtDNA was severely depleted under normoxia,
but not under hypoxia, and NRTI-treated adipose cells
were refractory to the inhibitory effects of hypoxia on TG
accumulation.
Differential ANGPTL4 expression was observed in adipose 
tissue sections, depending on their site of origin in the body
ANGPTL4 has been identified as an adipocytokine upreg-
ulated by fasting, PPAR agonists [13,23,24] and hypoxia
[14]. We first investigated whether hypoxia also induced
angptl4 gene expression in human primary adipocyte cul-
tures, as previously shown in endothelial cells. Quantita-
tive PCR performed on total RNA extracted from
adipocytes cultured under normoxic or hypoxic condi-
tions showed that angptl4 gene expression was 6.5 fold
increased by hypoxia compared to control (p < 0.001)
(Fig. 3A). Moreover, potential effect of NRTIs on angptl4
gene expression was evaluated and no modification could
be exhibited by NRTI treatment, neither in normoxic nor
in hypoxic conditions (Fig. 3A).
We therefore used ANGPTL4 expression in vivo as a surro-
gate marker for investigating the physiological relevance
of differential pO2-adipogenesis-angiogenesis states
according to the location of the adipose tissue. We ana-
lyzed ANGPTL4 expression by immunohistochemical
staining of adipose tissue sections (Fig. 3B) from subcuta-
neous (a), omental (b), and mammary fat deposits (c).
We also studied sections of proliferating adipose tissue
from pathological areas around adrenal medulla tumor
pheochromocytoma (d) and from the lipo-hypertrophic
zone of lipodystrophic patients treated for HIV infection
(e). ANGPTL4 protein was present in the cytoplasm of
mature adipocytes in visceral adipose tissue, but no labe-
ling was detected in the subcutaneous and mammary fat
pads (Table 1). However, the adipose tissue associated
with pathological conditions, around pheochromocy-
toma and in the lipohypertophic zone of HIV patients,
was stained. Staining for leptin, a well-known adipocyte
marker, was detected in all adipose tissue sections exam-
ined (Fig. 3B). Finally, immunohistochemical studies
showed that the differential expression of ANGPTL4
depended on the anatomical origin of the adipose tissue,
suggesting that the metabolic status of adipose tissue may
indeed depend on its location within the body.
Discussion
Previous studies have provided evidence to suggest that
pO2 variations and angiogenesis modulate adipogenesis
[16,17,25,26] indeed the high level of plasticity of adi-
pose tissue is regulated via the vasculature [27]. In the
present study, we found that O2 availability affected the
expression of genes encoding adipokines, such as leptin,
which has been shown to induce angiogenesis and to
influence angiogenic factors [28-30]. We found that the
production of leptin protein was associated with stabiliza-
tion of the transcription factor HIF-1α (Fig. 1C), confirm-
ing the results of previous studies showing that leptin is
encoded by a hypoxia-inducible gene [31]. TG accumula-
tion was inhibited in preadipocytes maintained in
hypoxia during adipogenesis, consistent with data
obtained in a rodent rodent preadipocyte cell line [12].
Yun et al. suggested that adipogenesis was regulated via
the inhibition of PPARγ 2 gene expression by the product
of the HIF-1-regulated gene DEC1/Stra13 [12]. Further-
more, The effects of adipose tissue metabolism, which
depends on O2 availability, on response to NRTI treat-
ment has been proposed as a model for investigating the
differential effects of anti-retroviral drugs [6]. In the
present work, we tested the hypothesis that the effects of
NRTI depend on pO2. We first demonstrated that the
effects of NRTI on mtDNA content were O2-dependent
(Fig. 2A and 2B), suggesting that mitochondria, which are
highly active in normoxic conditions, need to replicate
their mtDNA in such conditions, rendering them more
sensitive to NRTI polymerase-γ inhibition than cells main-
tained in hypoxia. Surprisingly, NRTI-treated cells were
refractory to the hypoxia-mediated inhibition of adipo-
genesis (Fig. 3C), suggesting that the consequences of
hypoxia may be profoundly modified by NRTI treatment.
In LD patients, NRTI-associated mtDNA depletion in adi-
pocytes has been reported to affect the function of mito-
chondrial respiratory proteins [6,8]. Under hypoxia,
mitochondrial respiration inhibitors have been shown to
induce the redistribution of intracellular O2 [32]. Hagen et
al. used the renilla luciferase system to determine intracel-
lular O2 concentrations. They showed that O2 was redis-
tributed to cells not registering hypoxia, thereby
preventing the stabilization of HIF-1α. If inhibition of the
mitochondrial respiratory chain restores intracellular O2
availability then, given that lipogenesis requires high pO2
levels, as shown in this study, NRTI-treated cells may not
register hypoxia and thus accumulate TG similarly to cells
in normoxic conditions. O2 is a major regulator of the gly-
colytic pathway and of the mitochondrial respiratory
chain. In particular, mitochondrial oxidative phosphor-
ylation generates a chemo-osmotic gradient favoring the
entry of pyruvate into the tricarboxylic acid (TCA) cycle toLipids in Health and Disease 2006, 5:27 http://www.lipidworld.com/content/5/1/27
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Differential effects of NRTI treatment on human adipose cells cultured under different pO2 Figure 2
Differential effects of NRTI treatment on human adipose cells cultured under different pO2. (A) Effects of NRTI 
treatment on mtDNA contents. Cells were cultured for 10 days as preadipocytes (P) or with Mix medium (A) under normoxia 
(20%) or in the presence of 100 μM DFO (DFO) plus a cocktail of 10 μM AZT and ddC (NRTI, black bars), or in the presence 
of 100 μM DFO but without the NRTI cocktail (C, hatched bars). Cell mtDNA was quantified and expressed per million cells 
(mtDNA/106 cells). n = 3, ** p < 0.001. (B) Effects of NRTI treatment on TG accumulation. Cells were cultured in the same exper-
imental conditions than in panel (A) and TG were quantified and data were normalized with respect to the control value 
obtained in adipocytes allowed to differentiate under normoxia condition (20% A, hatched bar, OD495 nm = 0.25). n = 3, ** p < 
0.001. (C) Effects of NRTI treatment on adipocyte marker expression. Cells were cultured in the same experimental conditions 
than in panel (A), RNA was extracted and expression of the PPARγ, leptin genes was followed by quantitative PCR. n = 2.
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ANGPTL4 expression study of adipose tissue sections Figure 3
ANGPTL4 expression study of adipose tissue sections. (A) Angptl4 is a target of hypoxia in human adipose cells. Quantita-
tive PCR analysis of ANGPTL4 mRNA in adipocytes (white bar), cultured for 24 hours in chemical DFO hypoxic condition 
(grey bar). n = 2, p < 0.001. (B) Differential ANGPTL4 and leptin expression in adipose tissue sections depending on the anatomical ori-
gin of the adipose tissue. We assessed ANGPTL4 (left panel) and leptin (right panel) levels by immunostaining subcutaneous (a), 
omental (b), and mammary (c) fat deposits and adipose tissues around a pheochromocytoma (d) and from the lipo-hyper-
trophic zone of lipodystrophic patients treated for HIV (e). Immunostaining with an isotypic control was carried out for each 
sample tested: a', b', c', d' and e'.
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generate citrate, a crucial step for fatty acid synthesis.
Under hypoxia, anaerobic glycolysis generates pyruvate
that does not enter the TCA cycle. This molecule is instead
transformed into lactic acid, decreasing the amount of cit-
rate available for fatty acid synthesis. Succinate accumula-
tion has been reported to link this mitochondrial TCA
intermediate to the cytosolic inhibition of HIF-1α prolyl
hydroxylase, leading to the stabilization and activation of
HIF-1α [33]. Metabolic regulation mechanisms of this
type add an additional level of complexity to the pattern
of HIF-1α-regulated gene expression.
LD syndrome highlights regional differences in adipocyte
biology. Studying the heterogeneity in function and
responsiveness of fat from visceral and subcutaneous
deposits could provide new insight in pathological proc-
ess. Indeed, differences in insulin action, lipolytic or
antilipolytic responses and cytokine production have
shown that the metabolic status of adipose tissues may
depend on their location in the body (see for review [10]).
However, little is known about quantitative or qualitative
differences in vascularization [26]. Endothelial progenitor
cells have been detected in the stroma vascular fraction
isolated from adipose tissue, providing further evidence
for a link vasculogenesis, angiogenesis and adipogenesis
[34]. However, no data are available regarding the micro-
circulation and pO2. Nevertheless, the presence of the
angiogenic factor VEGF, which is produced and secreted
in rat adipose tissue, has been shown to be dependent on
the fat deposit considered, being highest in omental
deposits[35]. In obese patients, visceral fat deposits have
been shown to release more VEGF and IL-6 than abdomi-
nal subcutaneous tissue [11]. The recently described
hypoxia-induced adipokine ANGPTL4 was found to be a
good candidate molecule for studies of the metabolic
states of adipose cells according to pO2 microenviron-
ment. ANGPTL4 was strongly expressed in the peri-adre-
nal adipose tissue around a pheochromocytoma and in
lipohypertrophic (table 1), in which adipose fat mass
increases, suggesting that through secretion of angiogen-
esis modulators adipocytes may have autocrine effects on
their own growth. In non-pathological tissues, only vis-
ceral adipose tissue was found to express ANGPTL4. If the
expression of this protein was associated with a hypoxic
microenvironment, then adipogenesis levels would be
expected to be low in that zone but NRTI treatment would
modify the adipogenic metabolism of cells that would
become refractory to hypoxia.
Our study shows that (i) Hypoxia may modify the adipo-
genic metabolism of primary human adipose cells; (ii)
Toxicity of NRTI depends of oxygen environment of adi-
pose cells; and (iii) The differential expression of
ANGPTL4 suggests modulation of pO2  environment
according to the anatomical origin of the adipose tissue.
Thus, our data suggest that the LD phenotype may be a
differential consequence of NRTI effects, depending on
the metabolic status of the targeted adipose tissues. How-
ever, more extensive investigations on the relationships
between hypoxia, angiogenesis and adipogenesis are
required to elucidate the physiopathology of adipose tis-
sue in LD or in obesity.
Methods
Cell culture, drug treatments and quantification of lipid 
accumulation
Fragments of waste adipose tissues collected from subcu-
taneous abdominal wall were obtained during cosmetic
surgery on healthy subjects. For studies using adipose tis-
sue from HIV-infected patients the samples were obtained
from waste abdominal fat in lipohypertrophic zone dur-
ing repair surgery. The tissue sample was cut into small
pieces and processed as previously described [36]. Preadi-
pocytes from the stromal vascular fraction were cultured
in medium (1:1 mixture of Ham's F12/Dulbecco's Modi-
fied Eagle's Medium (Invitrogen) supplemented with 20
mM HEPES, 10% decomplemented fetal calf serum, FCS,
and antibiotics). Confluent cells were allowed to differen-
tiate for 12 to 15 days. Their differentiation was favored by
adding a mixture (Mix) containing 8.5 nM insulin (Sigma
Aldrich), 1 μM dexamethasone (Sigma Aldrich), 250 nM
isobutyl methyl xanthine IBMX (Sigma Aldrich) and 1 μM
pioglitazone (generously provided by V. Zilberfarb) to the
medium. NRTI treatment was carried out by a nucleoside
analog cocktail consisting of 10 μM azidothymidine
(AZT) (Sigma Aldrich) and 10 μM 2'3' diolesoxycytosine
(ddC) (generously provided by Dr J. Leibowitch) to the
cell culture medium every two days. Hypoxia was
achieved by culturing cells in an atmosphere containing
1% O2 (incubator IG750 Jouan) or in the presence of 100
μM deferoxamine mesylate (DFO) (Sigma Aldrich). Lipid
accumulation was quantified by staining triglycerides
with Oil Red O solution (Sigma Aldrich) and TG were
quantified as previously described [37].
Table 1: In vivo Angptl4 expression in adipose tissues
origin of adipose tissues n expression levels
Abdo s/s cut 9 -
Abdo omental 3 +++
Mammary 10 -
Pheochromocytoma 3 +++
Lipo-hypertrophic zone of LD 3 +++
Adipose tissue immunostaining was performed on subcutaneous 
abdominal (Abdo s/s cut), intraperitoneal (Abdo omental) or 
mammary adipose tissues, on fat depots around area of 
pheochromocytoma tumor (Pheochromcytoma) and lipo-
hypertrophic zone of lipodystrophic treated HIV-patients. (n) 
indicates the number of different samples tested. Expression levels are 
indicated by + signs.Lipids in Health and Disease 2006, 5:27 http://www.lipidworld.com/content/5/1/27
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Immunocytochemical and immunohistochemical analysis
Human preadipocytes were plated on glass slides. HIF-1α
and leptin levels were assessed in cells fixed in 4% parafor-
maldehyde and quenched in 0.2 M NH4Cl. Cells were
blocked by incubation with 2% bovine serum albumin
and 2% SVF in PBS. They were then incubated for 90 min-
utes at room temperature with a mAb against HIF-1α
(1:50, R&D Systems) or with a mAb against leptin (1:20,
Santa Cruz Biotechnology). Antibody binding was
detected by incubation with a goat anti-mouse IgG cou-
pled to FITC (1:100 Beckman Coulter) for HIF-1α, or a
goat anti-rabbit IgG coupled to cy3 (1/250, Amersham
Pharmacia Biotech) for leptin. The samples were then
examined under an epifluorescence microscope (Axio-
phot; Zeiss, Oberkochen, Germany).
Human adipose tissue was fixed overnight in 4% parafor-
maldehyde in PBS at 4°C; samples were then dehydrated
and embedded in paraffin. Sections (3 μm) were cut and
processed for immunohistochemistry. Paraffin was
removed from the sections, which were then treated with
peroblok (ZYMED) and incubated with the leptin-specific
antibody described above or with the antibody directed
against human ANGPTL4 used and validated by Le Jan et
al [14]. Sections were then incubated with the specific
substrate, using the Zymed kit method according to the
manufacturer's instructions (Sigma Aldrich). Sections
were dehydrated and viewed under a light microscope
(Leica).
Mitochondrial DNA quantification
Total DNA (nuclear and mitochondrial) from drug-
treated and untreated cells was collected in 100 μl elution
buffer with the QIAamp DNA Blood Mini Kit (QIAGEN),
and mtDNA was quantified by real-time PCR. For each
DNA extract, the nuclear gene encoding β-globin and the
mitochondrial 12S RNA gene were quantified separately,
as previously described [38]. Data were analyzed using
LightCycler Software version 3.5. β-globin genes were
quantified using the LightCycler-Control Kit DNA
(Roche).
Gene expression studies
For RT-PCR, the first-strand cDNA was synthesized from 1
μg of total RNA, using the Moloney murine leukemia
virus reverse transcriptase (Superscript II Plus, Invitro-
gen), according to the manufacturer's protocol. Controls
without reverse transcriptase were performed to exclude
DNA contamination. We amplified 100 ng of first-strand
cDNA with 1 U Taq polymerase (Invitrogen) and 250 μM
gene-specific sense- and antisense-primers (Invitrogen) in
a thermocycler (GeneAmp PCR System 9600, Perkin-
Elmer Cetus). We amplified the cDNAs for PPARγ with the
primers sense: 5'TTTCACTATGGAGTTCATGCTTGTG3',
antisense: 5'TTTTTGTGGATCCGACAGTTAAGA3'; for lep-
tin sense : 5'GCCTTCCAGAAACGTGATCC3', antisense :
5'GGCCAGCACGTGAAGAAGAT3'; VEGF sense :
5'TACCTCCACCATGCCAAGTG3', antisense
:5'GATGATTCTGCCCTCCTCCTT3'; for ANGPTL4 sense
5'CGTACCCTTCTCCACTTGGG and antisense 5'GCTCTT-
GGCGCAGTTCTTG, for PO (sense 5'GGCGACCT-
GGAAGTCAACT and antisense
5'CCATCAGCACCACAGCCTTC3'. cDNA levels were
quantified by real-time quantitative PCR performed on
Taqman AbiPrism 7700 Sequence Detector using Syber-
Green JumpStart TaqReadyMix kit. Analysis of the target
messages (ANGPTL4, PPARγ, Leptin, VEGF, PO) quantifi-
cation was done by measuring Ct and by using a standard
curve to determine the starting target message quantity as
described in [39]. Briefly, the standard curve was con-
structed with four-fold serial dilutions of cDNA obtained
from the differentiated adipocytes, known to express
strongly the PPARγ, leptin and VEGF gene. To ANGPTL4,
we used preadipocytes traited with DFO. We therefore
quantified in all samples transcripts of the PO gene encod-
ing human acidic ribosomal phosphoprotein PO ubiq-
uitly expressed as the endogenous RNA control and each
sample was normalized on the basis of its PO content.
Statistical analysis
Data were presented as means ± standard deviation (SD)
and analyzed by both one-way and two-way ANOVA pro-
cedures. A p value < 0.05 was considered statistically sig-
nificant, ** indicated p < 0.001.
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